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Abstract 
Background. In the last few years, it has been widely reported that proinflammatory and angi-
ogenic cytokines are important for the development and progression of multiple myeloma (MM).  
Objectives. To further validate and acquire more insight into this view we decided to check 
whether plasma levels of certain cytokines and their soluble receptors differ between MM patients 
and healthy subjects.  
Patients and Methods. The study was conducted in 76 MM patients aged 22 to 77 years (60±10 
years) and 35 healthy controls aged 20 to 63 years (33±10 years). Plasma levels of interleukin-6 
(IL-6), b-fibroblast growth factor (b-FGF), hepatocyte growth factor (HGF), vascular endothelial 
growth factor (VEGF) and transforming growth factor-β1 (TGF-β1), as well as soluble receptors for 
IL-6 (sIL-6R) and VEGF (sVEGF-R2) were measured using enzyme-linked immunosorbent assay 
(ELISA).  
Results. Significantly higher plasma levels of IL-6 (13.65±42.61 vs. 1.04±1.12 pg/ml, p=0.006), HGF 
(2174±2714 vs. 648±130 pg/ml, p<0.001), b-FGF (7.92±10.78 vs. 2.54±5.38 pg/ml, p<0.001) and 
sIL-6R (37.1±14.2 vs. 25.3±6.4 ng/ml, p=0.003) were observed in MM patients vs. healthy controls, 
respectively. Plasma sVEGF-R2 was significantly lower in MM patients than in controls (7518±2119 
vs. 8725±1281 pg/ml, respectively; p<0.001). We observed an inverse correlation between length 
of treatment and the level of sIL-6R, and TGF-β1 in plasma.  
Conclusions. Plasma levels of HGF, b-FGF, IL-6 and sIL-6R in MM patients were higher when 
compared to the control group. Antineoplastic therapy leads to a time-dependent decrease in 
plasma levels of sIL-6R, and TGF-β1 in MM patients. Blood plasma level of HGF is an optimal 
measure to differentiate patients in whom disease is progressing versus patients who respond to 
therapy. 
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Introduction 
Recent studies have confirmed the importance of 
soluble cytokines and their receptors in the biology of 
multiple myeloma (MM) [1-3]. The principal mecha-
nism of action of interleukin-6 (IL-6) in MM is most 
likely the inhibition of apoptosis of myeloma cells. It 
has been shown that the level of soluble receptors for 
IL-6 (sIL-6R) is elevated in myeloma patients com-
pared to healthy subjects, and its level correlates with 
 
Ivyspring  
International Publisher 
 Journal of Cancer 2014, Vol. 5 
 
http://www.jcancer.org 
519 
disease severity [3,4]. Currently, the serum level of 
sIL-6R is considered to be one of the prognostic fac-
tors in MM [4]. Vascular endothelial growth factor 
(VEGF) is one of the strongest drivers of angiogenesis. 
In MM, the binding of VEGF with its receptors, 
VEGF-R1 and VEGF-R2, induces angiogenesis and 
leads to exponential growth of the tumour. Further-
more, with the activation of these receptors, there is 
increased expression of integrins on the cell surface, 
which facilitates adhesion and migration [6, 7, 8]. In 
MM, the serum level of basic fibroblast growth factor 
(b-FGF) increases with disease progression. It was 
also found that myeloma cells express surface recep-
tor FGF-R3 (which is not found on normal lymphoid 
cells), divide more rapidly and undergo apoptosis less 
frequently than cells without FGF-R3. Effective anti-
proliferative treatment often causes a reduction in 
b-FGF levels in the serum of patients with MM 
[1,9,10]. Transforming growth factor-β1 (TGF-β1) is 
synthesized by almost all cells of the body. The in-
creased microvascular network in the bone marrow of 
patients with MM is likely the result of the plasma 
secretion of TGF-β1, which stimulates the release of 
platelet derived growth factor and thereby enhances 
angiogenesis [11]. Hepatocyte growth factor (HGF) 
has mitogenic, chemotactic, and morphogenic prop-
erties. It has a significant effect on the morphogenesis 
of new blood vessels and bone marrow stroma, and it 
stimulates the synthesis of angiogenic factors. Ele-
vated levels of HGF in the serum of patients with MM 
is associated with an unfavourable prognosis. Nu-
merous studies have shown that HGF is involved in 
the progression of MM, including damage to bone, 
angiogenesis, and myeloma cell adhesion to bone 
marrow stroma [12,13]. Studies indicate the im-
portance of the HGF-c-MET axis in the stimulation of 
proliferation and inhibition of apoptosis in MM cells 
[4,15,16]. 
The aim of this study was to compare the plasma 
levels of cytokines IL-6, VEGF, b-FGF, TGF-β1, HGF, 
and soluble receptors sIL-6R and sVEGF-R2 between 
patients with MM and healthy volunteers. 
Patients and methods 
Clinical characteristics of the study group 
 The study comprised 76 patients aged 22 to 77 
years (mean age 60 years, SD ± 10) with MM treated at 
the Department of Haematology, University Hospital, 
Krakow, Poland. The control group consisted of 35 
healthy volunteers aged 20 to 63 years (mean age 33 
years, SD ± 10). Both test and control groups were 
similar with respect to gender distribution. The group 
of patients with MM included 38 women and 38 men, 
F/M ratio = 1. The control group consisted of 19 
women (54.3%) and 16 men (45.7%) F/M ratio = 1.2. 
The diagnosis of MM was based on cytologic exami-
nation of bone marrow aspirate revealing at least 10% 
plasmocytes, the presence of monoclonal proteins in 
serum or urine, and bone osteolytic lesions. Patients 
with MM were divided into 2 groups, designated N 
for newly diagnosed, previously untreated, and S for 
patients undergoing antiproliferative treatment. 
Group N consisted of 29 patients (38.2%), while group 
S consisted of 47 people (61.8%). We subdivided 
group S into three groups, based on length of treat-
ment: S1 included patients undergoing treatment for 1 
to 2 years (n=13), S2 comprised patients undergoing 
treatment for 2 to 3 years (n=11), and S3 consisted of 
patients undergoing treatment for longer than 3 years 
(n=23). Additionally, any patient in group S under-
going treatment for more than a year was evaluated 
for response to antiproliferative therapy. Patients with 
MM were treated according to the guidelines of the 
Polish Myeloma Group. For patients under 65 years of 
age, first line treatment consisted of the CTD protocol 
(cyclophosphamide, thalidomide, and dexame-
thasone) followed by CTX and G-CSF combined with 
the auto-PBSCT procedure. Throughout treatment we 
continued thalidomide. In cases of disease recurrence, 
treatment consisted of bortezomib or lenalidomide in 
many cases. Patients over 65 years of age were treated 
either with the MPT (melphalan, prednisone, and 
thalidomide) or VMP (bortezomib, melphalan and 
prednisone) protocols. In cases of disease progression, 
lenalidomide and dexamethasone were given [17]. We 
evaluated whether there was progression of disease, 
resistance to treatment, or if treatment had a positive 
effect. These analyses were based on: assessment of 
bone marrow (the percentage of plasma cells in bone 
marrow biopsy), protein parameters (serum protein 
electrophoresis), biochemical parameters (serum 
C-reactive protein - CRP, β2 microglobulin, calcium), 
and complete blood count. During our testing we 
were unable to evaluate the clinical outcome of 
treatment in 6 patients, and therefore testing was 
conducted on the remaining group of 41 patients. Of 
these remaining patients 23 positively responded to 
treatment while 18 patients showed progressive MM 
which was resistant to therapy. The study was ap-
proved by the local Ethics Committee. 
Blood and plasma analysis 
Blood samples were collected between 7:30 and 
8:30 hours in sterile Vacutainer tubes (Becton Dickin-
son, New Jersey, USA) which contained an anticoag-
ulant (EDTA). The tubes were then centrifuged for 10 
minutes at 1,000 RPM. Plasma was pipetted into ster-
ile tubes (Nunc, Roskilde, Denmark) and stored at 
-70°C until analysis was performed. Biochemical as-
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says of lactate dehydrogenase (LDH), blood urea, 
creatinine, total calcium concentration in both groups 
and CRP, β2 microglobulins, serum protein electro-
phoresis in MM group were performed using stand-
ard methods. Results of blood counts were obtained 
via photo-optical and conductivity methods using a 
Cell-Dyn 1700 analyzer (Abbott, Abbott Park, USA). 
The plasma levels of VEGF, sVEGF-R2, IL-6, sIL-6R, 
b-FGF, HGF, and TGF-β1 were measured using ELISA 
assays (Quantikine, R&D Systems, Minneapolis, MN., 
USA). 
Statistical methods 
Results were subjected to statistical analysis. The 
normality of the distribution was tested using the 
Shapiro-Wilk test. We used Student's t-test for the 
analysis of independent variables, and the U 
Mann-Whitney test for the analysis of dependent 
variables. All calculations were performed using 
STATISTICA 10 PL software (StatSoft, Inc., USA) li-
censed to Jagiellonian University. Only results which 
had a p value <0.05 were considered statistically sig-
nificant. 
Result 
 Plasma levels of cytokines, their soluble recep-
tors, and the assessment of biochemical parameters in 
patients with MM versus the control group are pre-
sented (Tables 1 and 2). Elevations of HGF, b-FGF, 
IL-6, and sIL-6R were observed in the blood plasma of 
patients with MM as compared to the control group, 
whereas the plasma level of sVEGF-R2 was lower 
compared to the control group. Analyses revealed 
differences in the clinical values of erythrocytes, 
haemoglobin, haematocrit, platelet count, urea, cre-
atinine, and LDH activity in serum between MM pa-
tients and controls. We also analyzed concentrations 
of cytokines and their soluble receptors in MM pa-
tients paying attention to differences that may be at-
tributed to age and sex. The only differences noted 
between the sexes was the concentration of b-FGF, 
which was twice as high in males when compared 
with women (Table 3). We did not, however, observe 
any statistically significant differences attributed to 
age (Additional file 1: supplementary Table 1). We 
compared the levels of cytokines and soluble cytokine 
receptors, depending on the application and duration 
of disease treatment. Higher levels of TGF-β1 were 
observed in group N patients when compared to 
group S (Table 4). We further analyzed patients de-
pending on duration of therapy (Table 5). During ini-
tial therapy, mean plasma IL-6 levels decreased three 
fold compared to pre-treatment levels. However, in 
patients who were treated the longest, plasma levels 
of IL-6 rose to levels greater than those observed prior 
to initiation of treatment. Conversely, we observed a 
drop in plasma levels of sIL-6R and TGF- β1 as dura-
tion of disease and treatment increased. Decreased 
levels of VEGF, HGF, and b-FGF were noticed after 
initiation of therapy. Values of sVEGF-R2 were simi-
lar in all analyzed subgroups. We evaluated whether 
there was a relationship between length of therapy 
and tested cytokines/soluble cytokine receptors in the 
whole group of patients with MM. We observed an 
inverse correlation between length of treatment and 
the concentration of sIL-6R, and TGF-β1 in plasma 
(Table 6). Furthermore, we compared the level of cy-
tokines and soluble cytokine receptors, at various 
stages of disease progression. The analysis shows that 
the most useful parameter in evaluating the progres-
sion of multiple myeloma is the plasma level of HGF 
(Table 7). 
 
Table 1. Cytokines, their soluble receptors and routine labora-
tory plasma levels in multiple myeloma patients and healthy con-
trols. 
Parameter Study group p-value 
Patients with MM Healthy controls 
n mean±SD n mean±SD 
IL-6 (pg/ml) 65 13.65 ± 42.61 35 1.04 ± 1.12 0.006 
sIL-6R (ng/ml) 65 37.1 ± 14.2 35 25.3 ± 6.4 0.003 
VEGF (pg/ml) 65 56.8 ± 46.7 35 49.9 ± 49.9 NS 
sVEGF-R2 (pg/ml) 65 7518 ± 2119 35 8725 ± 1281 <0.001 
HGF (pg/ml) 76 2174 ± 2714 35 648 ± 130 <0.001 
b-FGF (pg/ml) 76 7.92 ± 10.78 35 2.54 ± 5.38 <0.001 
TGF- β1 (ng/ml) 76 12.41 ± 6.64 35 13.72 ± 8.17 NS 
WBC (K/μl) 66 5.56 ± 2.65 27 5.91 ± 1.38 NS 
RBC (M/μl) 66 3.53 ± 0.70 27 4.80 ± 0.67 <0.001 
Hb (g/dl) 66 11.2 ± 2.04 27 14.3 ± 1.94 <0.001 
Hct (%) 66 32.7 ± 6.24 27 42.6 ± 5.5 <0.001 
PLT (K/μl) 66 200.8 ± 86.7 27 270.1 ± 72.4 <0.001 
Urea (mmol/l) 42 8.15 ± 5.98 7 5.11 ± 1.75 0.011 
Creatinine (μmol/l) 42 128.5 ± 141.7 7 74.7 ± 10.99 0.020 
Calcium (mmol/l) 43 2.37 ± 0.35 7 2.35 ± 0.22 NS 
LDH (U/l) 37 431.4 ± 275.39 7 299.7 ± 55.79 0.012 
b-FGF, b-fibroblast growth factor; Hb, haemoglobin; Hct, haematocrit; HGF, 
hepatocyte growth factor; IL-6, interleukin-6; LDH, lactate dehydrogenase; MM, 
multiple myeloma; NS, not significant; PLT, blood platelets; RBC, red blood cells; 
sIL-6R, soluble IL-6 receptor; SD, standard deviation; sVEGF-R2, soluble VEGF 
receptor; TGF-β1, transforming growth factor-β1; VEGF, vascular endothelial 
growth factor; WBC, white blood cells. 
 
Table 2. Results of electrophoresis, CRP level, blood serum 
β2microglobulin, and the plasmocyte infiltration of bone marrow in 
MM patients. 
Parameter Patients with MM 
n mean ± SD 
Total Protein (g/l) 68 89.0 ± 20.8 
Albumin (g/l) 68 45.8 ± 10.4 
Alpha 1 globulin (%) 67 3.6 ± 1.8 
Alpha 2 globulin (%) 67 10.6 ± 7.9 
Beta globulin (%) 67 12.2 ± 9.2 
Gamma globulin (%) 67 25.3 ± 15.3 
CRP (mg/l) 17 14.95 ± 21.65 
β2 microglobulin (mg/l) 18 3.35 ± 1.76 
Plasmocyte infiltration of bone marrow (%) 37 45.8 ± 27.8 
CRP, C-reactive protein; MM, multiple myeloma; SD, standard deviation. 
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Table 3. Cytokines and their soluble receptors in male and female 
MM patients. 
  sex n mean ± SD p-value 
IL-6 (pg/ml) F 31 14.4 ± 43.2 0.596 
M 34 12.9 ± 42.7 
sIL-6R (ng/ml) F 31 39.3 ± 16.8 0.975 
M 34 35.1 ± 11.2 
VEGF (pg/ml) F 31 58.4 ± 45.7 0.519 
M 34 55.4 ± 48.1 
sVEGF-R2 (pg/ml) F 31 7577.4 ± 2120.2 0.542 
M 34 7464.0 ± 2148.4 
HGF (pg/ml) F 38 2021.3 ± 1783.0 0.897 
M 38 2327.8 ± 3421.8 
b-FGF (pg/ml) F 38 5.42 ± 7.13 0.020 
M 38 10.42 ± 13.11 
TGF- β1 (ng/ml) F 38 11.61 ± 5.87 0.466 
M 38 13.24 ± 7.33 
b-FGF, b-fibroblast growth factor; F, female; HGF, hepatocyte growth factor; IL-6, 
interleukin-6; M, male; MM, multiple myeloma; sIL-6R, soluble IL-6 receptor; SD, 
standard deviation; sVEGF-R2, soluble VEGF receptor; TGF-β1, transforming 
growth factor-β1; VEGF, vascular endothelial growth factor; 
 
Table 4. Comparison of levels of cytokines and soluble cytokine 
receptors in the treated versus untreated groups. 
Parameter Patients with MM, 
group N 
Patients with MM, 
group S 
p 
n x ± SD n x ± SD 
IL-6 (pg/ml) 22 17.2 ± 20.7  43 11.8 ± 38.5 NS 
sIL-6R (ng/ml) 22 42.9 ± 15.9  43 34.1 ± 12.4 NS 
VEGF (pg/ml) 22 64.5 ± 52.6  43 52.9 ± 43.4 NS 
sVEGF-R2 (pg/ml) 22 7734 ± 2007  43 7407 ± 2188 NS 
HGF (pg/ml) 29 2007 ± 1660  47 2277 ± 3210 NS 
b-FGF (pg/ml) 29 7.44 ±11.11  47 8.21 ± 10.69 NS 
TGF- β1 (ng/ml) 29 14.24 ± 7.00  46 11.26 ± 6.20 0.025 
b-FGF, b-fibroblast growth factor; HGF, hepatocyte growth factor; IL-6, interleu-
kin-6; MM, multiple myeloma; N, newly diagnosed patients, previously untreated; 
NS, not significant; S, patients remaining in treatment; sIL- 6R, soluble IL-6 recep-
tor; SD, standard deviation; SVEGF-R2, VEGF soluble receptor; TGF-β1, trans-
forming growth factor-β1; VEGF, vascular endothelial growth factor. 
 
Table 5. Comparison of plasma levels of cytokines and soluble 
cytokine receptors in patient subgroups according to treatment 
duration. 
Parameter Group n mean ± SD 
IL-6 (pg/ml) N 21 18.03 ± 51.83 
S1 12 7.21 ± 7.58 
S2 9 6.34 ± 7.96 
S3 16 19.80 ± 62.30 
sIL-6R (ng/ml) N 21 43.79 ± 15.72 
S1 12 34.02 ± 12.77 
S2 9 34.02 ± 13.72 
S3 16 32.92 ± 11.29 
VEGF (pg/ml) N 21 64.87 ± 53.90 
S1 12 71.69 ± 64.67 
S2 9 39.27 ± 29.72 
S3 16 40.68 ± 23.76 
sVEGF-R2 (pg/ml) N 21 7652 ± 2019 
S1 12 7874 ± 2545 
S2 9 6985 ± 1706 
S3 16 7278 ± 2143 
HGF (pg/ml) N 28 2001 ± 1690 
S1 13 2570 ± 3489 
S2 11 2186 ± 2306 
S3 16 2073 ± 4089 
b-FGF (pg/ml) N 28 7.71 ± 11.22 
S1 13 10.54 ± 15.83 
S2 11 7.10 ± 5.97 
S3 16 5.68 ± 6.07 
TGF- β1 (ng/ml) N 28 14.11 ± 7.09 
S1 13 11.91 ± 6.06 
S2 11 12.39 ± 7.95 
S3 16 9.60 ± 4.38 
b-FGF, b-fibroblast growth factor; HGF, hepatocyte growth factor; IL-6, interleu-
kin-6; MM, multiple myeloma; N, newly diagnosed patients, previously untreated, 
NS, not significant; S1, patients treated from 1 to 2 years; S2, patients treated from 2 
to 3 years; S3, patients treated for longer than 3 years; sIL-6R, soluble IL-6 receptor; 
SD, standard deviation; sVEGF-R2, soluble VEGF receptor; TGF-β1, transforming 
growth factor-β1; VEGF, vascular endothelial growth factor. 
Table 6. Analysis of correlation between duration of therapy and 
studied cytokines. 
 n r Spearman p 
IL-6 (pg/ml) 58 0.007 NS 
sIL-6R (ng/ml) 58 -0.304 0.02 
VEGF (pg/ml) 58 -0.243 NS 
sVEGF-R2 (pg/ml) 58 -0.100 NS 
HGF (pg/ml) 68 0.009 NS 
b-FGF (pg/ml) 68 -0.083 NS 
TGF- β1 (ng/ml) 68 -0.253 0.04 
b-FGF, b-fibroblast growth factor; HGF, hepatocyte growth factor; IL-6, interleu-
kin-6; NS, not significant; sIL-6R, soluble IL-6 receptor; sVEGF-R2, soluble VEGF 
receptor; TGF-β1, transforming growth factor-β1; VEGF, vascular endothelial 
growth factor. 
Table 7. Levels of cytokines and soluble cytokine receptors in 
various stages of disease progression. 
Parameter Patients with MM treated with antiproliferative 
therapy 
p 
Without disease progres-
sion 
With disease pro-
gression 
n mean ± SD n mean ± SD 
IL-6 (pg/ml) 20 4.14 ± 5.75  18 19.59 ± 58.15  NS 
sIL-6R (ng/ml) 20 31.2 ± 9.1  18 38.4 ± 15.4  NS 
VEGF (pg/ml) 20 47.4 ± 33.9  18 55.2 ± 54.0  NS 
sVEGF-R2 (pg/ml) 20 7591 ± 1612  18 7066 ± 2682 NS 
HGF (pg/ml) 23 1283 ± 1583  18 3555 ± 4498  <0.001 
b-FGF (pg/ml) 23 6.46 ± 9.17  18 9.71 ± 12.51  NS 
TGF-β1 (ng/ml) 22 10.84 ± 6.28  18 12.33 ± 6.33  NS 
b-FGF, b-fibroblast growth factor; HGF, hepatocyte growth factor; IL-6, interleu-
kin-6; MM, multiple myeloma; NS, not significant; sIL-6R, soluble IL- 6 receptor; 
SD, standard deviation; sVEGF-R2, soluble VEGF receptor; TGF-β1, transforming 
growth factor-β1; VEGF, vascular endothelial growth factor. 
 
Discussion 
 In our study we showed that patients with MM 
demonstrate characteristically increased plasma levels 
of HGF, b-FGF, IL-6R and decreased levels of 
sVEGF-R2. Antineoplastic therapy leads to a 
time-dependent decrease in plasma levels of sIL-6R, 
and TGF-β1 in MM patients. The analysis shows that 
the most useful parameter in evaluating the progres-
sion of multiple myeloma is the plasma level of HGF. 
The data we analyzed showed that plasma concentra-
tions of the selected cytokines are another element 
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which allows clinicians to evaluate disease progres-
sion as well as the effectiveness of treatment. Identi-
fying patients, in whom treatment is less effective 
may be one reason to suggest a change in therapy, 
however this requires further study. Our study was 
limited by age differences in the populations studied. 
A correlation analysis of the studied age-dependent 
parameters in both groups demonstrated that age 
does not affect any of these parameters in patients 
with MM, and demonstrated that the effect is directly 
proportional to HGF and VEGF levels in controls 
(Additional file 1: supplementary Table 2). This ob-
servation led to our conclusion that HGF level played 
a significantly greater role than age did on the results 
observed.  
Increased cytokine secretion by bone marrow 
stroma often plays a major role in the pathogenesis of 
some of the clinical signs of MM, such as bone disease. 
In our study, a statistically significant higher level of 
HGF, b-FGF, IL-6, and sIL-6R was observed in the 
blood plasma of MM patients as compared to the 
control group. Many studies have demonstrated that 
plasma levels of IL-6 and sIL-6R are elevated in pa-
tients with MM and correlate with the severity of the 
cancer [1,18-20]. Bataille et al. showed that in patients 
with stage III MM, based on the Durie and Salmon 
classification, levels of IL-6 were significantly higher 
compared to patients with stage I and II disease. In 
addition, it was noted that elevated levels of IL-6 in 
serum was a good predictor of the severity of the 
disease [18]. Rawstron et al. examined the expression 
of the CD126 antigen (α subunit of the receptor for 
IL-6), and found that it is only present in MM cells; it 
is not expressed in normal plasma cells. IL-6 leads to 
tumour growth, not only through direct stimulation 
of cell proliferation, but also via the inhibition of 
apoptosis of tumour plasma cells [1, 21]. Kyrstsonis et 
al. studied the levels of IL-6 in the serum of healthy 
individuals and patients with multiple myeloma 
treated with chemotherapy. The level of IL-6 in MM 
patients, which was significantly elevated before 
treatment started, decreased to undetectable values at 
the time of hematologic remission. A gradual increase 
in IL-6 was observed if relapse occurred [22]. 
 In our study we observed that anti-proliferative 
treatment has a significant effect on sIL-6 plasma lev-
els. The plasma level of this cytokine showed a nega-
tive correlation with the duration of treatment. 
Changes in the level of IL-6 in MM during treatment 
reflect the current ability to control the condition. The 
level of IL-6 decreases in the first years of treatment 
(group S1), when treatment is most effective. How-
ever, it increases with disease duration (S3), showing 
that MM progression is inevitable. 
VEGF and other proangiogenic cytokines play a 
vital role in the neovascularization of the bone mar-
row of patients with MM. Vacca et al. measured the 
area occupied by the small blood vessels in bone 
marrow specimens from MM patients and compared 
them to healthy individuals. The area of small blood 
vessels was significantly larger in patients with active 
MM compared to patients with an inactive form of the 
disease, monoclonal gammopathy of undetermined 
significance (MGUS), or healthy subjects [23,24]. In 
our study plasma levels of b-FGF and VEGF in pa-
tients with MM were higher compared to the control 
group, but this difference was statistically significant 
only for b-FGF. The role of b-FGF in the pathogenesis 
of MM has not yet been fully described. Plowright et 
al. observed ectopic expression of FGFR-3 in ap-
proximately 25% of patients with MM [9]. It was ob-
served that when cells expressing FGFR-3 were au-
tonomous of IL-6, there was a reduced level of apop-
tosis and enhanced proliferative response following 
stimulation with IL-6. In the presence of FGF-9 and 
FGFR-3 ligand, test cells rapidly proliferated and were 
more viable than cells with normal expression of 
FGFR-3. Di Raimondo et al. divided patients into two 
groups based on the stage of their cancer (disease 
confined to the bone marrow vs. extramedullary lo-
cation) [25]. In both groups of patients significantly 
elevated levels of VEGF and b-FGF were observed in 
the bone marrow as compared to serum. Elevated 
levels of VEGF and b-FGF in the bone marrow and 
serum of patients with MM was also reported by Zhu 
et al. [26]. The level of these cytokines was signifi-
cantly increased in the bone marrow compared to 
peripheral blood, which indicates that the bone mar-
row is likely to be a major site of production. Many 
researchers have confirmed that pathological plasma 
cells secrete factors that stimulate angiogenesis 
[27-29]. In our study we observed that the mean 
plasma levels of sVEGF-R2 were decreased in MM 
patients compared to the control group. It seems that 
the formation of new blood vessels is probably in-
creased in the bone marrow stroma of MM patients 
when compared to the control group of healthy vol-
unteers. However, sVEGF-R2 is associated with vas-
cular endothelial cells in healthy individuals, which 
seems to be confirmed by the observations obtained in 
the present study [27].  
Studies regarding the effects of treatment on the 
degree of angiogenesis in multiple myeloma are in-
conclusive. Rajkumar et al. compared microvessel 
density (MVD) in 13 patients before and after treat-
ment with high-dose chemotherapy and subsequent 
stem cell transplantation [30]. There was no statisti-
cally significant reduction in MVD in patients who 
achieved partial or complete remission after treat-
ment. On this basis it was concluded that increased 
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bone marrow vascularity is not associated with re-
gression, even in patients during complete hemato-
logic remission. On the other hand, Sezer et al. and 
Sjak-Shie et al. reported a reduction of MVD in the 
bone marrow during chemotherapy [31,32]. Sezer et 
al. observed decreased MVD index in patients re-
sponding to treatment, while the index remained 
unchanged in the remaining patients [33]. The dis-
crepancies in the results of the individual authors 
seem to indicate the limited value of MVD as an in-
dependent marker of the efficacy of anti-angiogenic 
therapy. During normal endothelial cell death, MVD 
decreases, whereas when endothelial cell death is 
secondary to increased neoplastic cells, MVD in-
creases. Therefore, during anti-angiogenic therapy 
MVD ratio can decrease, increase or remain the same. 
A decrease in MVD during anti-angiogenic therapy 
suggests that the treatment is effective. However, lack 
of such an effect does not necessarily mean that the 
drug treatment is ineffective. The above considera-
tions clearly indicate that using MVD as the sole pa-
rameter to determine the effectiveness of an-
ti-angiogenic therapy is insufficient. Thus, it is im-
portant to search for another marker of angiogenesis 
that correlates to the clinical effect of treatment. In our 
study we observed significant negative correlation 
between bone marrow infiltration by cancer cells and 
the plasma level of VEGF and TGF-β1. When com-
paring patients in different stages of disease progres-
sion, however, variances in these markers showed no 
statistical significance. Thus, one can conclude that 
disease progression, i.e., an increase in plasmocyte 
infiltration of the bone marrow, correlates with a de-
crease in the level of VEGF and TGF-β1 in blood 
plasma (Additional file 1: supplementary Table 3). 
Plasma levels of HGF such as those observed in 
our study may be useful in determining the prognosis 
and clinical activity in patients with MM. While ex-
amining autocrine stimulation in MM, Borset et al. 
reported that HGF secreted by the plasma cells stim-
ulates the pathological c-MET receptor present on 
myeloma cells [14]. In addition to autocrine stimula-
tion, Derksen et al. suggest that HGF is also produced 
in a paracrine manner by bone marrow stromal cells 
[33]. Neoplastic plasma cells present in the bone 
marrow, along with the "network of cytokines" and 
bone marrow stromal cells are jointly responsible for 
the destructive changes and osteolytic bone lesions. 
TGF-β1 is a cytokine associated with an increase or 
decrease in bone osteolysis, and also has profibrotic 
action [33,34]. However, in our study the mean plas-
ma levels of TGF-β1 in MM patients and the control 
group did not show any statistically significant dif-
ferences. 
Among cytokines that were the best predictors of 
MM progression in our study, HGF showed very clear 
differences between patients grouped by clinical cri-
teria of MM progression. HGF level was approxi-
mately two times higher in people with severe pro-
gression compared to patients without progression. 
Supplementary Material 
Additional File 1:  
Supplementary tables 1-3.  
http://www.jcancer.org/v05p0518s1.pdf 
Competing Interests 
The authors have declared that no competing 
interest exists. 
References 
1. Chou T. Multiple myeloma: recent progress in diagnosis and treatment. J Clin 
Exp Hematop. 2012; 52: 149-59. 
2. Ishikawa H, Tsuyama N, Liu S, et al. Accelerated proliferation of myeloma 
cells by interleukin-6 cooperating with fibroblast growth factor receptor 
3-mediated signals. Oncogene. 2005; 24: 6328-6332. 
3. Kovacs E. Interleukin-6 leads to interleukin-10 production in several human 
multiple myeloma cell lines. Does interleukin-10 enhance the proliferation of 
these cells? Leuk Res. 2010; 34: 912-916.  
4. Tsirakis G, Pappa CA, Kaparou M, et al. The relationship between soluble 
receptor of interleukin-6 with angiogenic cytokines and proliferation markers 
in multiple myeloma. Tumour Biol. 2013; 34: 859-864. 
5. Stompór T, Zabłocki M, Pankrac K. Renal involvement in multiple myeloma. 
Pol Arch Med Wewn. 2012; 122: 443-448. 
6. Byzova TV, Goldman CK, Pampori N, et al. A mechanism for modulation of 
cellular responses to VEGF: activation of the integrins. Mol Cell. 2000; 6: 
851-860. 
7. Giatromanolaki A, Bai M, Margaritis D, et al. Hypoxia and activated 
VEGF/receptor pathway in multiple myeloma. Anticanc Res. 2010; 30: 
2831-2836. 
8. Marković O, Marisavljević D, Cemerikić V, et al. Expression of VEGF and 
microvessel density in patients with multiple myeloma: clinical and prognos-
tic significance. Med Oncol. 2008; 25: 451-457. 
9. Jurczyszyn A, Wolska-Smoleń T, Sobociński M, et al. Serum concentrations of 
proangiogenic cytokines in patients with multiple myeloma. Acta Haematol 
Pol. 2003; 34: 40. 
10. Plowright EE, Li Z, Bergsagel PL, et al. Ectopic expression of fibroblast growth 
factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. 
Blood. 2000; 95: 992-998. 
11. Matsumoto T. Abe M. TGF-ß-related mechanisms of bone destruction in 
multiple myeloma. Bone. 2011; 48: 129-134. 
12. Iwasaki T, Hamano T, Ogata A, et al. Clinical significance of vascular endo-
thelial growth factor and hepatocyte growth factor in multiple myeloma. Br J 
Haematol. 2002; 116: 796-802. 
13. Sezer O, Jacob C, Eucker J, et al. Serum levels of the angiogenic cytokines basic 
fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) 
and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol. 
2001; 66: 83-88. 
14. Borset M, Lien E, Espevik T, et al. Concomitant expression of Hepatocyte 
Growth Factor/Scatter Factor and the Receptor c-MET in Human Myeloma 
Cell Lines. J Biol Chem. 1996; 271: 24655-24661. 
15. Mahtouk K, Tjin EP, Spaargaren M, et al. The HGF/MET pathway as target for 
the treatment of multiple myeloma and B-cell lymphomas. Biochem Biophys 
Acta. 2010; 1806: 208-219. 
16. Ro TB, Holien T, Fagerli UM, et al. HGF and IGF-1 synergize with SDF-1α in 
promoting migration of myeloma cells by cooperative activation of 
p21-activated kinase. Exp Hematol. 2013; 41: 646-655. 
17. Dmoszyńska A, Walter-Croneck A, et al. Guidelines of Polish Myeloma Group 
concerning diagnosis and therapy of multiple myeloma and other plasmacytic 
dyscrasias for 2013. Acta Haematologica Polonica. 2013; 44: 3-47. 
18. Bataille R, Jourdan M, Zhang XG, et al. Serum levels of interleukin-6, a potent 
myeloma cell growth factor, as a reflect of disease severity in plasma cell dys-
crasias. J Clin Invest. 1989; 84: 2008-2011. 
19. Usnarska-Zubkiewicz L, Mazur G, Wróbel T, et al. Expression of serum vas-
cular endothelial growth factor correlates with clinical outcome in multiple 
myeloma. Pol Arch Med Wewn. 2003;110: 719-724. 
20. Usnarska-Zubkiewicz L. Level of interleukin-6 (IL-6), soluble interleukin-6 
receptors (sIL-6R) and tumor necrosis factor alpha (TNF-alpha) in untreated 
and progressing multiple myeloma. Pol Arch Med Wewn. 1998; 99: 30-37. 
 Journal of Cancer 2014, Vol. 5 
 
http://www.jcancer.org 
524 
21. Rawstron AC, Fenton JA, Ashcroft J, et al. The interleukin-6 receptor al-
pha-chain (CD126) is expressed by neoplasmatic but not normal plasma cells. 
Blood. 2000; 96: 3880-3886. 
22. Kyrstsonis MC, Dedoussis G, Baxevanis C, et al. Serum interleukin-6 (IL-6) 
and interleukin-4 (IL-4) in patients with multiple myeloma (MM). Br J Haemat. 
1996; 92: 420-422.  
23. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma 
cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel 
progression of human multiple myeloma. Blood. 1999; 93: 3064-3073. 
24. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progres-
sion in multiple myeloma. Br J Haematol. 1994; 87: 503-508. 
25. Di Raimondo F, Azzaro MP, Palumbo G, et al. Angiogenic factors in multiple 
myeloma: higher levels in bone marrow than in peripheral blood. Haemato-
logica. 2000; 85: 800-805. 
26. Zhu AZ, Fleischer M, Bush A. Elevated serum concentrations of fibroblast 
growth factor (FGF) in patients with multiple myeloma (MM). Proc Annu 
Meet Am Soc Clin Oncol. 1999; 18A: 155-161. 
27. Gupta D, Treon SP, Shima Y, et al. Adhesion of human multiple myeloma cell 
lines to bone marrow stromal cells stimulates vascular endothelial growth 
factor secretion: therapeutic application. Leukemia. 2001; 15: 1950-1961. 
28. Mądry K, Dwilewicz-Trojaczek J, Suleiman W, Paszkowska-Kowalewska M, 
Ziarkiewicz-Wróblewska B. Angiogenesis in bone marrow of myelodysplastic 
syndrome patients. Pol Arch Med Wewn. 2007; 117: 145-150. 
29. Wątorek E, Paprocka M, Duś D, Kopeć W, Klinger M. Endostatin and vascular 
endothelial growth factor: potential regulators of endothelial progenitor cell 
number in chronic kidney disease. Pol Arch Med Wewn. 2011; 121: 296-302 
30. Rajkumar SV, Fonseca R, Witzig TE, et al. Bone marrow angiogenesis in 
patients achieving complete response after stem cell transplantation for mul-
tiple myeloma. Leukemia. 1999; 13: 469-472.  
31. Sezer O, Niemöller K, Kaufmann O. Prognostic relevance of bone marrow 
microvessel density in multiple myeloma. Book of Abstracts, VIIIth Interna-
tional Myeloma Workshop, Banff, Canada; 2001; 156: 80.  
32. Sjak-Shie N. The role of angiogenesis and VEGF in multiple myeloma. Ab-
stract Book from Mayo Clinic Symposium “Innovative Research In Multiple 
Myeloma”. Amelia Island, USA. 2001: 210-216.  
33. Derksen PWB, de Gorter DJJ, Meijer HP, et al. The hepatocyte growth fac-
tor/Met pathway controls proliferation and apoptosis in multiple myeloma. 
Leukemia. 2003; 17: 764-774. 
34. Wójcik KA, Koczurkiewicz P, Michalik M, Sanak M. Transforming growth 
factor-β1-induced expression of connective tissue growth factor is enhanced in 
bronchial fibroblasts derived from asthmatic patients. Pol Arch Med Wewn. 
2012; 122: 326-332. 
